cfDNA clonality and copy-number driver identification methods revealed significant mutual exclusivity among predicted truncal driver cfDNA alterations for EGFR and ERBB2, in effect distinguishing tumor-initiating alterations from secondary alterations.Dataset reveals subclonal structures and emerging resistance in advanced solid tumors. This evidence concerns the gene EGFR and neoplasm.